Press Releases

Investor Resources
Contact Us
Investor ResourcesPress Releases

Press Releases

Cardiol Therapeutics Announces $15 Million Bought Deal Public Offering


May 5, 2021

Cardiol Therapeutics Announces First Patient Enrolled in LANCER, a Phase II/III Outcomes Trial in High-risk Patients Hospitalized with COVID-19


April 28, 2021

Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx™


April 12, 2021

Cardiol Therapeutics Announces Filing of 2020 Year-end Financial Statements and MD&A


April 1, 2021

Cardiol Therapeutics Appoints Dr. Andrew Hamer as New Chief Medical Officer


March 30, 2021

Cardiol Therapeutics Submits Application for Uplisting to the Nasdaq and Raises Proceeds of Over $10 Million from Exercise of Warrants and Options


March 2, 2021

Cardiol Therapeutics Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19


January 21, 2021

Cardiol Therapeutics to Participate in Upcoming Virtual Investor Conferences


January 7, 2021

Cardiol Therapeutics Announces Completion of Phase I Clinical Study of CardiolRx™


December 22, 2020

2025 Cardiol Therapeutics. All right reserved.